antiparasiti

Rapanone (2,5-Dihydroxy-3-tridecyl-[1,4]benzoquinone) is a natural benzoquinone that is a potent and selective inhibitor of human synovial PLA2.

Antiparasitic agent-24 (Compound 14a) is an antiparasitic compound with EC50 values of 0.005 μM for L. maj, 0.069 μM for L. don, 0.82 μM for T. brucei, and 4.1 μM for T. cruzi.

Antiparasitic agent-26 (Compound 8) is an antiparasitic compound that effectively inhibits the growth of Naegleria fowleri, with an IC50 of 22.87 μM (trophozoite stage) and 25.16 μM (cyst stage). It exerts its antiparasitic effects by inducing programmed cell death, which includes cytosolic calcium accumulation, mitochondrial membrane potential collapse, ATP synthesis inhibition, ROS accumulation, and chromatin condensation. Antiparasitic agent-26 can be utilized in research on primary amoebic meningoencephalitis (PAM).

Antiparasitic agent-25 (Compounds 11) is an orally active antiparasitic compound. It inhibits the invasion and replication capabilities of parasites and has an irreversible effect on Toxoplasma gondii. The agent significantly reduces the replication rate of Toxoplasma gondii, with an IC50 value of 6.33 μM, and exhibits low cytotoxicity, having a CC50 value of 285 μM.

Antiparasitic agent-21 (compound 28) exhibits selective antiparasitic activity against Naegleria fowleri, with an EC50 of 0.92 μM. Additionally, Antiparasitic agent-21 demonstrates excellent blood-brain barrier permeability.

Antiparasitic agent-22 (Compound 24) is a broad-spectrum antiparasitic compound that inhibits the procyclic form of T. brucei, L. infantum, and L. tropica with IC50 values of 2.41, 5.95, and 8.98 μM, respectively, and the amastigote form of L. infantum with an IC50 of 8.18 μM. It also shows inhibitory activity against the P. falciparum W2 strain with an IC50 of 0.155 μM. Additionally, Antiparasitic agent-22 exhibits low cytotoxicity in THP1 cells, with a CC50 of 64.16 μM.

Antiparasitic agent-27 (Compound 2) is a potent antiparasitic compound targeting Leishmania infantum with an IC50 of 3.1 μM. It induces cell cycle arrest in the G0/G1 phase and enhances reactive oxygen species (ROS) production to trigger programmed cell death, showing promise for visceral leishmaniasis (VL) research.

Antiparasitic agent-4 (compound 4q) exhibits high antiparasitic activity with an IC50 of 8.51 μM for Leishmania infantum (L. infantum) and an IC50 of 2.20 μM for Trypanosoma cruzi (T. cruzi). It is also cytotoxic against HepG2 cells with a CC50 of 18.97 μM [1].

Antiparasitic agent-6 (compound 5b) demonstrates selective antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 of 3.89 μM and exhibits cytotoxicity against HepG2 cells with a CC50 of 13.64 μM [1].

Antiparasitic agent-2 (compound 8a) exhibits potent antiparasitic activity against Leishmania infantum (L. infantum) and Trypanosoma cruzi (T. cruzi) with IC50s of 7.28 μM and 2.30 μM, respectively, and demonstrates moderate cytotoxicity against HepG2 cells with a CC50 of 26.79 μM [1].

Antiparasitic agent-8 (Compound 9) exhibits potent antiparasitic activity against Hymenolepis nana, with low levels of cytotoxicity [1].

Antiparasitic agent-7 (compound 5d) exhibits specific antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 value of 2.85 μM and demonstrates cytotoxicity against HepG2 cells with a CC50 value of 10.61 μM [1].

Antiparasitic agent-10 (Compound 94) is a potent anti-parasitic agent with significant anti-schistosomal activity, particularly against adult Schistosoma mansoni, making it a promising candidate for Schistosomiasis research as a treatment option [1].

Antiparasitic agent-5 (compound 8h) exhibits potent selectivity against Leishmania infantum (L. infantum) with an IC50 value of 2.50 μM and displays cytotoxic effects on HepG2 cells with a CC50 value of 6.78 μM [1].

Antiparasitic agent-9 (compound 47) is a highly effective and orally administered antiparasitic agent, demonstrating significant efficacy against the human parasite [1].

Antiparasitic Agent-14 is a potent antiparasitic compound with demonstrated cytotoxicity and antiparasitic activity, effectively inhibiting the growth of trypomastigote and amastigote forms [1].

Antiparasitic Agent-17 (compound 5u), an orally active antiparasitic, demonstrates inhibition against both Chloroquine-sensitive (Pf3D7) and Chloroquine-resistant (PfK1) strains, with IC50 values of 0.96 μM and 1.67 μM, respectively [1].

Antiparasitic agent-18 (compound 3a) exhibits potent and selective antiprotozoal activity, effectively inhibiting T. brucei (EC50 = 0.4 µM), T. cruzi (EC50 = 0.21 µM), and L. donovani (EC50 = 0.26 µM) [1].

Antiparasitic Agent-20 (Compound 1p) exhibits broad-spectrum activity as a parasitic inhibitor, demonstrating efficacy against T. brucei and T. cruzi with EC50 values of 0.09 µM and 14.1 µM, respectively [1].

Antiparasitic Agent-19 (Compound 40) is a broad-spectrum antiparasitic with minimal toxicity to Trypanosoma brucei, Leishmania infantum, and Trypanosoma cruzi [1].

Suramin Sodium Salt (BAY-205) is a sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.

Dextrorotation nimorazole phosphate ester TFA is an anti-anaerobic and anti-parasitic agent.

Levorotation nimorazole phosphate ester TFA is an anti-anaerobic and anti-parasitic agent.

Oxantel Pamoate (Oxantel embonate) is used as an Antinematodal agent.